Envisagenics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Envisagenics, Inc. - overview
Established
2014
Location
New York, NY, US
Primary Industry
Biotechnology
About
Founded in 2014 and based in New York, US, Envisagenics, Inc. operates as a developer of predictive analytics platforms that allow scientists to translate basic discoveries into therapies. Maria Luisa Pineda (CEO) and Martin Akerman (CTO) are the co-founders of the company. In June 2024, Envisagenics, Inc.
raised USD 25 million in Series B funding from Bristol-Myers Squibb, Empire State Development, Third Kind Venture Capital, and Red Cell Partners. The series B funding values Envisagenics, Inc. at USD 142. 99 million post-money.
The company’s pipeline includes the SpliceCore® platform, which specializes in the identification and validation of drug targets by leveraging RNA sequencing data. SpliceCore® enhances the discovery of novel splicing-derived targets and elucidates the mechanisms of antisense drug regulation. In addition, SpliceIOTM, a branch of SpliceCore®, focuses on identifying tumor-specific neoepitopes for immunotherapy. The organization plans to use the June 2024 funding to accelerate product development efforts and enhance business offerings.
Current Investors
Breakout Ventures, Accelerate Long Island, SV Angel
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Bioinformatics, Healthcare IT, Pharmaceutical Research & Development
Website
www.envisagenics.com/
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Envisagenics, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member, Scientific Advisory Board | BM | ||||||
| Board of Directors, Audit Committee Chair and Compensation Committee Chair | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.